Distinct skeletal muscle molecular responses to pulmonary rehabilitation in chronic obstructive pulmonary disease: A cluster analysis by Kneppers, Anita E. M. et al.
Distinct skeletal muscle molecular responses to
pulmonary rehabilitation in chronic obstructive
pulmonary disease: a cluster analysis
Anita E.M. Kneppers1*, Roy A.M. Haast2,3, Ramon C.J. Langen1, Lex B. Verdijk4, Pieter A. Leermakers1, Harry R. Gosker1,
Luc J.C. van Loon4, Mitja Lainscak5,6 & Annemie M.W.J. Schols1
1Department of Respiratory Medicine, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre+, Maastricht, The
Netherlands, 2Department of Cognitive Neuroscience, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, The Netherlands, 3Maastricht Centre for
Systems Biology, Maastricht University, Maastricht, The Netherlands, 4Department of Human Biology, NUTRIM School of Nutrition and Translational Research in
Metabolism, Maastricht University Medical Centre+, Maastricht, The Netherlands, 5Division of Cardiology, General Hospital Murska Sobota, Murska Sobota, Slovenia,
6Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
Abstract
Background Pulmonary rehabilitation (PR) is a cornerstone in the management of chronic obstructive pulmonary disease
(COPD), targeting skeletal muscle to improve functional performance. However, there is substantial inter-individual variability
in the effect of PR on functional performance, which cannot be fully accounted for by generic phenotypic factors. We
performed an unbiased integrative analysis of the skeletal muscle molecular responses to PR in COPD patients and
comprehensively characterized their baseline pulmonary and physical function, body composition, blood profile, comorbidi-
ties, and medication use.
Methods Musculus vastus lateralis biopsies were obtained from 51 COPD patients (age 64 ± 1 years, sex 73% men, FEV1, 34
(26–41) %pred.) before and after 4 weeks high-intensity supervised in-patient PR. Muscle molecular markers were grouped by
network-constrained clustering, and their relative changes in expression values—assessed by qPCR and western blot—were re-
duced to process scores by principal component analysis. Patients were subsequently clustered based on these process scores.
Pre-PR and post-PR functional performance was assessed by incremental cycle ergometry and 6 min walking test (6MWT).
Results Eight molecular processes were discerned by network-constrained hierarchical clustering of the skeletal muscle
molecular rehabilitation responses. Based on the resulting process scores, four clusters of patients were identified by
hierarchical cluster analysis. Two major patient clusters differed in PR-induced autophagy (P < 0.001), myogenesis
(P = 0.014), glucocorticoid signalling (P < 0.001), and oxidative metabolism regulation (P < 0.001), with Cluster 1 (C1;
n = 29) overall displaying a more pronounced change in marker expression than Cluster 2 (C2; n = 16). General baseline
characteristics did not differ between clusters. Following PR, both 6 min walking distance (+26.5 ± 8.3 m, P = 0.003) and peak
load on the cycle ergometer test (+9.7 ± 1.9 W, P < 0.001) were improved. However, the functional improvement was more
pronounced in C1, as a higher percentage of patients exceeded the minimal clinically important difference in peak workload
(61 vs. 21%, P = 0.022) and both peak workload and 6 min walking test (52 vs. 8%, P = 0.008) upon PR.
Conclusions We identified patient groups with distinct skeletal muscle molecular responses to rehabilitation, associated with
differences in functional improvements upon PR.
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Introduction
Chronic obstructive pulmonary disease (COPD) is increasingly
recognized as a complex chronic disease with extra-
pulmonary manifestations and comorbidities, including skele-
tal muscle dysfunction.1 Skeletal muscle dysfunction in COPD
arises from structural and metabolic alterations such as a loss
of muscle mass, a shift in fibre type distribution, decreased
oxidative capacity, and mitochondrial dysfunction.2 Impor-
tantly, besides affecting physical functioning and health-
related quality of life,3 skeletal muscle dysfunction is a predic-
tor of mortality independent of lung function.4,5
In clinically stable COPD patients, exercise training is cur-
rently themost potent intervention to improve skeletal muscle
function. As such, exercise training forms a cornerstone in
pulmonary rehabilitation (PR) in patients with COPD. However,
despite the overall positive effects of exercise training on mus-
cle mass and function at the group level, there is substantial
inter-individual variability in the effect of PR on skeletal muscle
function.6–9,2,10 The sources of this variability currently remain
unexplained but may be better understood when we improve
our comprehension of the underlying skeletal muscle molecu-
lar response pattern. In the older population, which is prone to
the loss of muscle mass and strength (i.e. sarcopenia), the ex-
ercise response can be blunted due to impaired skeletal mus-
cle regeneration.11 This potentially results from an impaired
induction of skeletal muscle remodelling-related processes,
as reflected by a blunted induction of protein degradation,12
anabolic resistance,13 and a delayed or blunted satellite cell
response.11 Similarly, the exercise response in COPD patients
may be limited by impaired satellite cell mediated skeletal
muscle regeneration.14 Furthermore, we recently showed an
elevated basal activity of skeletal muscle remodelling-related
processes in COPD patients.15 This may hinder the normal
induction of these processes during skeletal muscle recovery
after disuse or upon exercise training.12
Several studies assessed molecular markers of remodelling-
related processes upon exercise training in COPD
patients,16,17,10,18 but none report a clear differential rehabili-
tation response between predefined phenotypic categories,
for example, based on body composition. This may be partially
due to the limited sample size in most of these studies or the
individual assessment of a limited selection of markers, which
often display a large variation. Nevertheless, age, body
composition, and comorbidities, such as metabolic and heart
diseases, have been weakly associated with the functional
response to rehabilitation.19,20,16 Other studies, however,
report inconclusive or even contradicting results,17,21,22,9,6–8
strongly indicating that these phenotypic factors do not fully
account for the variability in rehabilitation responses.
In the current study, we take a clustering approach to—for
the first time—unbiasedly address inter-individual heteroge-
neity in the skeletal muscle molecular response to PR of
patients with advanced COPD.
Materials and methods
Study design and participants
We selected COPD patients from a prospective observa-
tional study conducted in the in-patient PR unit at the
University Clinic Golnik. The study design has previously
been published23 (ClinicalTrials.gov identifier: NCT0255
0808). The study was approved by the Slovenian National
Medical Ethics Committee (Ljubljana, Slovenia) and was
carried out in accordance with the ethical standards laid
down in the 1964 Declaration of Helsinki and its later
amendments, and all participants provided written in-
formed consent. Patient selection for the current analysis
was based on completion of the 4 week rehabilitation pro-
gramme and availability of both a pre-rehabilitation and
post-rehabilitation muscle biopsy specimens, yielding 51
patients.
Pulmonary and physical function
Spirometry was used to obtain FEV1, FVC, and their ratio
(FEV1/FVC).
24 Physical function was assessed with the 6 min
walking test (6MWT)25 and by measurement of peak load
(W) and peak oxygen consumption (VO2, mL/kg/min) by an
incremental load cycling cardiopulmonary exercise test.26 In
addition, the improvements in physical function were
categorized by the minimal clinically important difference
(MCID; 6MWT: 25 m,27 peak load: 10 W28).
Body composition
Whole body dual-energy X-ray absorptiometry was used to
assess total and appendicular (i.e. arms and legs) fat mass
and fat-free mass at baseline, as previously described.23 Fat
mass index (FMI), fat-free mass index (FFMI), and appendicu-
lar skeletal muscle mass index were calculated as the ratio of
mass to height2 (kg/m2). Presence of muscle mass depletion
was defined by the cut-offs for appendicular skeletal muscle
mass index (<7.23 kg/m2 for men; <5.76 kg/m2 for
women).29 Bioelectrical impedance (BIA; QuadScan 4000;
Bodystat, Douglas, United Kingdom) was performed pre-PR
and post-PR as previously described23 and was used to assess
the change in FMI and FFMI upon PR.
Skeletal muscle molecular analyses
Pre-PR and post-PR biopsies were obtained from the vastus
lateralis muscle of the dominant leg by needle biopsy, one
day (≥20 h) after the last exercise test. Muscle tissue was
snap-frozen in liquid nitrogen and stored at 80°C until
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processed for molecular analyses; mRNA levels and protein
abundance of mediators and regulators of muscle mass and
metabolism were determined by RT–qPCR and western blot-




Details on the clustering analyses are provided in Supporting
Information. Briefly, molecular rehabilitation responses, cal-
culated as the percentage change from pre-rehabilitation
values, were grouped by network-constrained hierarchical
clustering of the markers. The resulting processes were
named based on enrichment of gene ontology (GO) biological
processes. Data dimensionality was reduced by computing a
single score for each process using principle component anal-
ysis. Subsequently, patients were hierarchically clustered
based on their individual process scores. Analyses were per-
formed in Python using the scikit-learn library, and results
were visualized using Graph-tool.
Statistics
After checking for normality, rehabilitation responses were
tested by paired-sample t-test. Between-group differences
were tested by independent sample t-test (two groups),
by one-way analysis of variance with Bonferroni post-hoc
comparisons (>2 groups), or by their non-parametric or
categorical equivalents. Correlations between molecular
processes were tested using Pearson’s correlation coeffi-
cient, and between-group differences in correlations were
tested by a Fisher’s r-to-z transformation. Analyses were
performed using SPSS Statistics (version 22.0, IBM Corp.,




Fifty-one patients were included in the analyses, with subject
characteristics displayed in Table 1. The patient group
consisted mostly out of men, current smokers, and 76% of
patients completed the PR without an exacerbation. Based
on the Global Initiative for Chronic Obstructive Lung Disease
classification,30 most patients had severe (stage III; 53%) to
very severe COPD (stage IV; 33%), and 60% of patients had
muscle mass depletion.
Functional and skeletal muscle molecular
rehabilitation responses in chronic obstructive
pulmonary disease patients
Following PR, both 6 min walking distance (+26.5 ± 8.3 m,
P < 0.01) and peak load on the cycle ergometer test
(+9.7 ± 1.9 W, P < 0.001) were improved. Moreover, 25 pa-
tients (51%) exceeded the MCID on the 6MWT, and 17 pa-
tients (40%) exceeded the MCID for peak load upon PR.
Using data from all 51 patients, eight molecular processes
(i.e. P1–P8) were discerned by network-constrained hierarchi-
cal clustering of the skeletal muscle molecular rehabilitation
responses (Figure 1A, Supporting Information, Table S1) and
were named based on gene ontology term overrepresenta-
tion as indicated in Supporting Information, Table S1. In gen-
eral, P1 (autophagy) related mRNA expression was
decreased, whereas autophagy-related protein phosphoryla-
tion and expression were increased after PR (Figure 1B). Fur-
thermore, P2 (AKT/mTOR signalling) related mRNA
expression, and protein phosphorylation and expression were
predominantly increased upon rehabilitation (Figure 1B). Sim-
ilarly, P3 (myogenesis) related mRNA and protein expression
and P4 [oxidative phosphorylation capacity (OXCAP)] and P5
(mitophagy, FUNDC1/DNM1L) related protein expression
were increased upon rehabilitation, whereas P6 (mitophagy,
PRKN) related protein expression was decreased (Figure
1B). Furthermore, P7 (glucocorticoid signalling) related inhib-
itory phosphorylation seemed to increase upon rehabilita-
tion, and in line with this, glucocorticoid signalling-related
downstream mRNA expression was decreased (Figure 1B).
Despite the significant decrease in mRNA expression of tran-
scriptional regulators of mitochondrial biogenesis (TFAM and
PPRC1) and the increase in a regulator of mitochondrial qual-
ity (PINK1), P8 (oxidative metabolism regulation) related
markers displayed no consistent overall pattern of change
upon rehabilitation (Figure 1B).
Identification of patient clusters with differential
skeletal muscle molecular rehabilitation responses
Both the functional and skeletal muscle molecular rehabilita-
tion responses displayed a substantial inter-individual varia-
tion. To gain insight in the determinants of this variation, an
unbiased approach was used to classify patients based on
their molecular rehabilitation responses. To this end, one pro-
cess score per identified molecular process was computed by
principle component analysis, with component loadings indi-
cated in Supporting Information, Table S2. Four clusters
(C1–4) of patients were identified by hierarchical cluster anal-
ysis based on process scores, using a cut-off based on the lo-
cal optimum in silhouette score (Figure 2A and 2B). C3 and C4
had an insufficient sample size (n = 4 and n = 2, respectively)
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for the statistical detection of relevant group differences and
were therefore omitted in further analyses.
C1 (n = 29) and C2 (n = 16) differed in rehabilitation-
induced modulation of autophagy, myogenesis, glucocorti-
coid signalling, and oxidative metabolism regulation and
tended to differ by regulation of OXCAP (Figure 2C,
Supporting Information, Table S3). Specifically, the differ-
ence in rehabilitation-induced change in autophagy markers
between C1 and C2 was mainly reflected by a differential
change in SQSTM1, MAP 1LC3B, BECN1, BNIP3, ULK1,
GABARAPL1, and OPTN mRNA expression (Supporting Infor-
mation, Table S4). Although both clusters displayed an
overall increase in autophagy-related protein expression, a
differential change in MAP 1LC3BI and a tendency towards
a differential change in MAP 1LC3BII/I were observed
(Supporting Information, Table S4). Conversely, the differ-
ential regulation of myogenesis was only reflected by a sig-
nificant difference in the rehabilitation-induced change in
MYOD1 and CDH15 mRNA expression (Supporting Informa-
tion, Table S4). In contrast to myogenesis, the differential
regulation of glucocorticoid signalling consisted of a differ-
ential rehabilitation-induced change in all related markers,
although FOXO3 mRNA did not reach significance
(Supporting Information, Table S4). The difference in the
rehabilitation-induced modulation of oxidative metabolism
regulation was reflected by a differential change in PINK1,
OPA1, FIS1, COX4I1, MYH2, MFN1, TFAM, PPARGC1A,
PPRC1, PPARGC1B, PRKN, MYH1, and SOD2 mRNA expres-
sion (Supporting Information, Table S4). Interestingly, al-
though the tendency towards a differential regulation in
Table 1. Baseline subject characteristics
Whole group Cluster 1 Cluster 2 P valuea
n = 51 n = 29 n = 16
Demographics
Age, years 64 ± 1 64 ± 2 65 ± 2 ns
Sex, m/f (% male) 37/14 (73) 21/8 (72) 11/5 (69) ns
Smoking status <0.1
Current, n (%) 44 (88) 24 (83) 16 (100)
Former, n (%) 6 (12) 5 (17) 0 (0)
Completion of PR ns
Without exacerbation, n (%) 39 (76) 23 (79) 11 (69)
With exacerbation, n (%) 12 (24) 6 (21) 5 (31)
Pulmonary function
FEV1, % predicted
b 34 [26–41] 34 [26–41] 38 [29–44] ns
FVC, % predicted 79 ± 3 80 ± 3 77 ± 5 ns
FEV1/FVC, %
b 33 [26–42] 31 [26–40] 33 [28–46] ns
Physical function
6MWT, m 344.68 ± 15.44 352.59 ± 22.11 348.00 ± 20.94 ns
Peak load, W 62.96 ± 3.30 62.81 ± 4.81 65.20 ± 5.51 ns
Peak VO2, mL/kg/min 11.75 ± 0.58 12.31 ± 0.85 11.35 ± 0.77 ns
Body composition
BMI, kg/m2 24.8 ± 0.6 24.2 ± 0.7 25.5 ± 1.3 ns
FMI, kg/m2 7.8 ± 0.3 7.4 ± 0.4 8.3 ± 0.7 ns
FFMI, kg/m2 16.9 ± 0.4 16.7 ± 0.5 16.9 ± 0.9 ns
ASMI, kg/m2 6.6 ± 0.2 6.5 ± 0.2 6.9 ± 0.4 ns
Muscle mass depletion, n (%) 30 (60) 20 (69) 7 (47) ns
Blood profile
Triglycerides, mmol/L 1.28 ± 0.08 1.16 ± 0.10 1.46 ± 0.14 <0.1
HDL cholesterol, mmol/L 1.77 ± 0.09 1.80 ± 0.10 1.73 ± 0.16 ns
LDL cholesterol, mmol/L 3.01 ± 0.15 2.77 ± 0.19 3.25 ± 0.26 ns
LDL/HDL, ratio 1.94 ± 0.14 1.65 ± 0.14 2.21 ± 0.27 <0.1
HOMA-IRb 3.40 [1.80–6.70] 3.70 [1.95–5.75] 2.90 [1.85–8.00] ns
Comorbidities
Long-term oxygen therapy, n (%) 20 (39) 11 (38) 5 (31) ns
Heart failure, n (%) 8 (16) 5 (17) 2 (13) ns
Ischemic heart disease, n (%) 4 (8) 3 (10) 0 (0) ns
Atrial fibrillation, n (%) 1 (2) 1 (3) 0 (0) ns
Arterial hypertension, n (%) 21 (41) 10 (34) 8 (50) ns
Cholesterolaemia, n (%) 14 (27) 6 (21) 5 (31) ns
Type 2 diabetes mellitus, n (%) 7 (14) 5 (17) 1 (6) ns
6MWT, 6 min walk test; ASMI, appendicular skeletal muscle mass index; BMI, body mass index; FEV1, forced expiratory volume in 1 s; FFMI,
fat-free mass index; FMI, fat mass index; FVC, forced vital capacity; HDL, high-density lipoprotein; HOMA-IR, homeostatic model of insulin
resistance; IQR, interquartile range; LDL, low-density lipoprotein; PR, pulmonary rehabilitation. Due to the insufficient sample size, individ-
ual values for Cluster 3 (n = 4) and Cluster 4 (n = 2) are not depicted in this table. Data expressed as mean ± SEM unless indicated
otherwise.
aSignificance of between group (Cluster 1 vs. Cluster 2) comparisons assessed by independent sample t-test, Mann–Whitney U-test, or χ2
test.
bMedian [IQR].
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Figure 1 Molecular network and network-constrained hierarchical clustering of molecular rehabilitation responses. (A) Network-constrained clusters
revealing eight distinct processes (P), as indicated with different colours. (B) Molecular rehabilitation responses. The literature-based molecular net-
work is indicated as lines between molecular markers. Circles represent mRNA markers; pentagons represent protein markers. Numbers correspond
to individual markers as depicted in Supporting Information, Table S1.
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Figure 2 Hierarchical clustering of patients. (A) Silhouette scores for n clusters (mean ± SEM). Clustering based on raw molecular rehabilitation re-
sponses (marker values; i.e. no data reduction) is indicated in grey; clustering based on eight process scores is indicated in black. (B) Patients individual
silhouette coefficient values per cluster. (c) Dendrogram and clustered heatmap of individual marker rehabilitation responses (Z-scores) and process
scores.
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OXCAP was not apparent at the marker level, a significant
rehabilitation-induced increase in NDUFB8, SDHB, MT-CO1,
ATP5F1A, and TOMM20 protein expression was observed
for C1, while these markers remained unaltered in C2
(Supporting Information, Table S4).
Association between muscle molecular
rehabilitation responses
To assess whether a differential response at the process and
marker level resulted in a differential coordination between
processes, the correlations between scores of the eight iden-
tified processes were computed and compared between the
two clusters (Figure 3).
Differential correlations for C1 and C2 were observed be-
tween autophagy and oxidative metabolism regulation, be-
tween AKT/mTOR signalling and OXCAP, and between
mitophagy (FUNDC1/DNM1L) and mitophagy (PRKN) (all
P < 0.05) (Figure 3). In addition, AKT/mTOR signalling
tended to be differentially correlated with myogenesis
(P = 0.06), mitophagy (PRKN) (P = 0.07), and glucocorticoid
signalling (P = 0.05) (Figure 3). Moreover, oxidative metab-
olism regulation tended to be differentially correlated with
OXCAP (P = 0.07) and glucocorticoid signalling (P = 0.09)
(Figure 3).
Cluster characteristics and functional rehabilitation
responses
C1 and C2 did not differ significantly in demographics, pulmo-
nary function, or body composition (Table 1) nor comorbidi-
ties or use of medication (Table 1, Supporting Information,
Table S5). Likewise, C1 and C2 did not differ in baseline values
of the functional parameters (Table 1) and average
rehabilitation-induced change in FFMI or FMI assessed by
BIA (Supporting Information, Figure S1). Furthermore, these
clusters did not differ significantly in the average
rehabilitation-induced change in 6MWT or peak load (Figure
4A and 4B). However, a pronounced and significant increase
in 6MWT was observed in C1, whereas the change in
6MWT did not reach significance in C2 (Figure 4A). Similarly,
a pronounced and significant rehabilitation-induced increase
in peak load was observed in C1 but not in C2 (Figure 4B).
Categorization of rehabilitation responses based on the
MCID revealed that the distribution of change in peak load
differed between C1 and C2, with a larger amount of patients
exceeding the MCID in C1 (61 vs. 21%, P < 0.05) (Figure 4C).
In accordance, C1 contained more patients that exceeded the
MCID for both the 6MWT and peak load than C2 (52 vs. 8%,
P < 0.01) (Figure 4C).
Discussion
To our knowledge, this study is the first to perform unbiased
clustering of COPD patients based on their skeletal muscle
molecular response to PR. Using this approach, we show that
clustering based on the molecular response to PR leads to the
identification of patient groups who differ by their functional
response to PR.
Variability in the response to pulmonary
rehabilitation
Study participants followed a supervised, high-intensity in-
patient PR programme, which targeted skeletal muscle using
a comprehensive exercise training programme.31 In line with
previous studies,32 PR improved physical performance
assessed by 6MWT and peak workload on a cycle ergometer
test, but the effect was highly variable. We measured a panel
of molecular markers that are important for exercise-induced
skeletal muscle mass and metabolic plasticity33–36 and, simi-
larly, observed high variability in the rehabilitation-induced
changes in skeletal muscle molecular marker expression
levels. Therefore, molecular markers were clustered into pro-
cesses and assessed within the context of co-clustered
markers. Subsequently, an integrative clustering approach
was used for unbiased identification of patient groups with
a differential skeletal muscle molecular response to PR.
Patient clusters with differential skeletal muscle
molecular rehabilitation responses
We identified two major patient clusters, which differed in
both the direction and the magnitude of the molecular re-
sponse to PR. Overall, C1 displayed the most pronounced
changes in markers of autophagy, myogenesis, glucocorticoid
signalling, oxidative metabolism regulation, and OXCAP in re-
sponse to PR.
Specifically, C1 displayed a change in autophagy-related
marker expression reflective of a decrease in autophagy and
a corresponding decrease in glucocorticoid signalling-related
mRNA expression upon PR, as is in line with the PR-response
in previous studies.16 Furthermore, corresponding to previ-
ous observations,10,18,16 AKT/mTOR signalling was induced
upon PR, resulting in an increased capacity and stimulatory
signalling of protein synthesis. In keeping with an induction
of anabolic signalling upon PR in C1, proliferation marker ex-
pression was mostly increased. However, in contrast to previ-
ous studies,10,16 mRNA expression of the myogenic
differentiation markers MYOD1 and CDH15 were reduced,
while mRNA expression of the fusion marker MYMK was in-
duced upon PR in C1. Furthermore, a decrease in expression
of oxidative metabolism regulation markers was observed in
Distinct skeletal muscle molecular responses to PR in COPD 317
Journal of Cachexia, Sarcopenia and Muscle 2019; 10: 311–322
DOI: 10.1002/jcsm.12370
C1. Nevertheless, this does not negate the previously re-
ported importance of oxidative metabolism regulation in
the coordination of exercise training-induced metabolic alter-
ations.37 Indeed, as anticipated upon exercise training,38
OXCAP protein expression was increased upon PR in C1.
Moreover, the PR-induced modulation of mitophagy-related
markers in C1 is in agreement with an important role for
mitochondrial dynamics and mitophagy in the regulation of
mitochondrial quality upon exercise training, as reviewed by
Drake et al.37 Together, these data indicate a relative de-
crease in catabolic signalling, a relative increase in anabolic
signalling, and an increase in mediators of oxidative metabo-
lism upon PR in C1, which strikingly reflects a normal re-
sponse to exercise training.39 Importantly, the ‘normal’
Figure 3 Associations between molecular rehabilitation responses. Each square displays a scatter plot and regression line of the processes indicated on
the x and y axis, for both Cluster 1 and Cluster 2. Differences between correlations were tested by a Fisher’s r-to-z transformation and indicated with a
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molecular response observed in C1 was accompanied by a
strong improvement in physical functioning in this cluster,
as determined by an increase in peak load on the cycle er-
gometer test and an improvement in walking distance in
the 6MWT.
In C2, both the functional and molecular responses to PR
were less pronounced. This cluster significantly differed from
C1 in the rehabilitation-induced regulation of autophagy,
myogenesis, glucocorticoid signalling, and oxidative metabo-
lism regulation. Specifically, expression of autophagy-related
mRNA and glucocorticoid signalling markers remained unal-
tered, or even increased upon PR in C2, which is in line with
previous observations,10,18 and may be due to disease-
related factors such as hypoxia or systemic inflammation.40,41
However, an early transient induction of catabolic processes
is also evident upon exercise and may play an important role
in muscle regeneration.42 Furthermore, the differential regu-
lation of myogenesis is reflected by a differential change in
the expression of specific markers. Interestingly, the reduc-
tion in the myogenesis markers MYOD1 and CDH15, and in-
duction in MYMK mRNA expression upon PR in C1, was
previously shown to be reflective of late-stage muscle regen-
eration.43,44 Conversely, the apparent increase in MYOD1 and
CDH15 mRNA expression, together with only a tendency to-
wards an increase in MYMK upon PR in C2, is reflective of
an earlier phase of muscle regeneration.43,44 Despite differ-
ences in the regulation of autophagy, myogenesis, and gluco-
corticoid signalling between C1 and C2, these processes
correlate similarly in both clusters, which shows that there
is no cluster-specific dissociation between these processes.
This may indicate that, with respect to muscle mass plasticity,
both clusters display a normal physiological response to PR
but may reflect distinct phases of PR-induced muscle
remodelling.
Interestingly, we found a tendency towards a differential
association between oxidative metabolism regulation and
OXCAP in Clusters 1 and 2 and a differential correlation be-
tween protein turnover and mitochondrial turnover regula-
tory processes. This supports previous studies showing a
correlation between tissue remodelling and bioenergetics
pathways that were altered in COPD36,43,45 and adds that this
alteration may be present only in a subgroup of patients.
Figure 4 Functional rehabilitation responses per cluster. Individual rehabilitation-induced changes. (A) Distance (metres) walked in 6 min walk test
(6MWT), n = 28/15. (B) Peak load (W) on a cycle ergometer test, n = 23/14. Data expressed as mean ± SD. (C) Percentage of patients with a change
in 6MWT, peak load, or both, exceeding the minimal clinically important difference (MCID; 6MWT: 25 m, peak load: 10 W). *P < 0.05, **P < 0.01,
***
P < 0.001, indicating significance of within-group rehabilitation responses or significance of differences between indicated groups.
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Indeed, as expected upon exercise training,39 C1 displayed an
increase in OXCAP markers upon PR, reflecting a restoration
of the oxidative metabolic machinery. This is corroborated
by the decreased expression of oxidative metabolism regula-
tion markers, as a normalization of metabolism-related mRNA
has previously been shown in late-stage muscle regenera-
tion.43,46 Conversely, in C2, oxidative metabolism regulation
and OXCAP were statistically unaltered, although oxidative
metabolism regulation seemed to increase upon PR. Further-
more, C2 displayed a strong induction in PINK1mRNA expres-
sion, which plays an important role in the regulation of
mitochondrial quality.47 Together, this suggests that the oxi-
dative metabolic machinery is incompletely restored in C2,
which may indicate that this process is impaired—as previ-
ously suggested in COPD48—or yet ongoing.
Potential drivers of cluster differences
Compellingly, and in line with previous studies,22,7,6,9,49 base-
line variables did not seem predictive of the muscle molecular
or functional response, as patient clusters did not differ in
baseline values of functional parameters, demographics, pul-
monary function, body composition, presence of comorbidi-
ties, or use of medication. Furthermore, both the current
physiological and molecular data do not provide clear indica-
tions of a ‘defective’ response in either cluster. Rather, we
propose that molecular differences between clusters are re-
flective of distinct phases of muscle remodelling, which may
be due to differences in the speed by which the remodelling
process occurs and/or the timing of initiation of muscle
remodelling-related processes upon PR. Interestingly, a dif-
ferential response to PR may reflect the underlying cause of
exercise limitation,50 including reduced muscle capillarization
and neuromuscular function as reported upon ageing,12,11
which delays or slows PR-induced muscle mass and metabolic
remodelling processes. This may be influenced by lifestyle
factors, which is corroborated by the tendency towards a dif-
ference in smoking status and blood lipid profile between the
clusters. Alternatively, the molecular changes reflecting an
early stage of muscle remodelling may originate from an im-
paired progression through regulating processes, preventing
their late-stage normalization, as may be the case for
myogenesis.51 However, the drivers of differential clustering
remain elusive and will be an important target for future
investigations.
Strengths and limitations
We acknowledge that future longitudinal studies are needed
to discern a potential defect in muscle mass and metabolic
plasticity from a differential progression of these processes.
Nevertheless, the use of a relatively short intervention period
was likely critical in the identification of clusters with molec-
ular differences reflective of distinct phases of the muscle re-
modelling process.
As we aimed to address the variability in the skeletal mus-
cle rehabilitation response between COPD patients, no
healthy control group was included. Furthermore, although
no PR-induced change in FFMI was detected by BIA, we did
not measure changes in muscle mass using a sensitive mea-
sure such as CT or MRI. Therefore, we cannot confirm our as-
sumption that C1 displays a more ‘healthy’ response to PR
than C2. However, it is unlikely that the delivered training
load differed between clusters, as the training programme
was conducted in a controlled, supervised in-patient setting.
Moreover, the training modality was based on baseline char-
acteristics, which did not differ between clusters.
The current study population was characterized by severe
COPD and a high prevalence of muscle mass depletion. There-
fore, distribution of patients among clusters cannot be di-
rectly extrapolated to the general COPD population. In line,
it should be noted that aside from the two extensively
discussed major clusters, two other patient clusters have
been identified. We chose to omit these two very small clus-
ters in further analysis, rather than recursively merging clus-
ters based on their hierarchical structure, because they
showed a distinct molecular response to PR. However, these
clusters may thus be clinically meaningful and call for future
investigation.
To support identification of robust, clinically relevant sub-
groups, patients were clustered based on process scores.
The physiological relevance of the identified processes is sub-
stantiated by the separation of two mitophagy processes that
have been reported in literature52 and was achieved by inclu-
sion of prior knowledge of the molecular network into the
marker clustering.53 To this end, we relied on well-
established knowledge of their interactions and previous un-
biased network analyses of ‘omics’ data.36,45 In contrast to
these studies, we have performed a targeted analysis of a se-
lection of molecular markers, which can be confined in future
studies as several markers show a low contribution to the
process scores. Nevertheless, component loadings did not im-
ply single biomarkers for the identified processes. Moreover,
assessment of single marker expression proved important for
the interpretation of observed differences in processes, cer-
tainly in the context of temporal responses, and therefore re-
mains necessary for obtaining insight in the mechanisms
underlying muscle dysfunction in COPD.
Conclusions
Based on the cluster-based analysis, no specific cluster with
‘non-responders’ was identified, reinforcing that exercise
training should form a cornerstone of PR to improve
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skeletal muscle function in advanced COPD. However, this
study identifies two major clusters of COPD patients with
a differential muscle molecular rehabilitation response,
which may be reflective of distinct phases of muscle remod-
elling, and corresponds to a differential gain in physical
functioning.
Identification of the drivers of these differential temporal
responses will provide an opportunity for personalized inter-
ventions optimizing the exercise training response. We pro-
pose that, next to detailed analyses of baseline lifestyle
factors such as smoking, diet and physical activity, and lung
function impairments and blood gasses, future studies should
investigate muscle intrinsic differences that determine the ki-
netics of the muscle molecular response to PR. This could
open up new avenues for pharmacological and nutritional in-
terventions to optimize the skeletal muscle functional im-
provements upon PR.
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